Gilead Sciences Stock Investor Sentiment

GILD Stock  USD 73.25  0.24  0.33%   
About 64% of Gilead Sciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Gilead Sciences suggests that many traders are alarmed. Gilead Sciences' investor sentiment overview provides quick insight into current market opportunities from investing in Gilead Sciences. The current market sentiment, together with Gilead Sciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Gilead Sciences stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

36

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Gilead Sciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Gilead Sciences.
Gilead Sciences stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Gilead daily returns and investor perception about the current price of Gilead Sciences as well as its diversification or hedging effects on your existing portfolios.

Gilead Historical Sentiment

Although Gilead Sciences' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Gilead, such as negative comments on social media and news outlets, may cause fear in the market and push Gilead Sciences' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Gilead.
  

Gilead Sciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Gilead Sciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Gilead Sciences Historical Investor Sentiment

Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Gilead Sciences.

Gilead Sciences Maximum Pain Price across 2024-03-28 Option Contracts

Gilead Sciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Gilead Sciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Gilead Sciences' options.
16 hours ago at finance.yahoo.com         
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
Yahoo News
a day ago at finance.yahoo.com         
Acquisition by Andrew Dickinson of 3025 shares of Gilead Sciences subject to Rule 16b-3
Yahoo News
a day ago at finance.yahoo.com         
TipRanks Perfect 10 List These 3 Top-Scoring Stocks Are Sending a Bullish Signal
Yahoo News
2 days ago at businesswire.com         
Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors
businesswire News
2 days ago at benzinga.com         
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
benzinga news
2 days ago at finance.yahoo.com         
Winn Awards Help Physicians Solve Healthcare Disparities
Yahoo News
3 days ago at zacks.com         
Gilead Sciences Stock Moves -0.04 percent What You Should Know
zacks News
3 days ago at gurufocus.com         
Gilead Sciences Inc at Leerink Partners Global Biopharma Conference Transcript
Gurufocus Stories at Macroaxis
3 days ago at investorplace.com         
Wall Streets Favorite Biotech Stocks 3 Names That Could Make You Filthy Rich
sbwire news
3 days ago at gurufocus.com         
Gilead Sciences Inc at TD Cowen Health Care Conference Transcript
Gurufocus Stories at Macroaxis
few days ago at investing.com         
Gilead finalizes CymaBay acquisition to bolster liver disease treatments
Investing News at Macroaxis
few days ago at investing.com         
Gilead reduces 2024 earnings guidance after completing CymaBay takeover
Investing News at Macroaxis
few days ago at seekingalpha.com         
Gilead completes CymaBay acquisition but negative impact on 2024 EPS
seekingalpha News
six days ago at finance.yahoo.com         
PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum DelveInsight Estimates a Diverse Pipeli...
Yahoo News
six days ago at finance.yahoo.com         
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Yahoo News
Far too much social signal, news, headlines, and media speculation about Gilead Sciences that are available to investors today. That information is available publicly through Gilead media outlets and privately through word of mouth or via Gilead internal channels. However, regardless of the origin, that massive amount of Gilead data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Gilead Sciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Gilead Sciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Gilead Sciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Gilead Sciences alpha.

Gilead Sciences Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
Gilead Sciences Signs Yet Another RD Alliance for Multi-Target Cancer Therapies
03/06/2024
2
HIV prevention drugs known as PrEP are highly effective, but many at risk dont know about it
03/13/2024
3
Dr. Welsh Coaching, LLC Launches Leadership Development Program Navigating Success
03/18/2024
4
Gilead Helps Launch Trkiyes First HIV Testing Week
03/19/2024
5
Investors Heavily Search Gilead Sciences, Inc. Here is What You Need to Know
03/20/2024
6
Clinical trial results show new Penn technology could be the key to fighting brain cancer
03/21/2024
7
Gilead reduces 2024 earnings guidance after completing CymaBay takeover
03/22/2024
8
Gilead Sciences Inc at TD Cowen Health Care Conference Transcript
03/25/2024
9
Acquisition by Andrew Dickinson of 3025 shares of Gilead Sciences subject to Rule 16b-3
03/27/2024
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.